Canntab Therapeutics Limited

$0.00+0.00%(+$0.00)
TickerSpark Score
54/100
Mixed
80
Valuation
55
Profitability
55
Growth
48
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTABF research report →

52-Week Range0% of range
Low $0.00
Current $0.00
High $0.01

Companycanntab.ca

Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.

CEO
Richard C. Goldstein
IPO
2017
HQ
Markham, ON, CA

Price Chart

+0.00% · this period
$0.00$0.00$0.00Nov 26Jun 02Nov 28

Valuation

Market Cap
$3.89K
P/E
-0.05
P/S
0.66
P/B
-0.61
EV/EBITDA
-0.46
Div Yield
0.00%

Profitability

Gross Margin
23.68%
Op Margin
-1570.07%
Net Margin
-1257.49%
ROE
-376.90%
ROIC
-222.05%

Growth & Income

Revenue
$293.36K · 0.00%
Net Income
$-3,689,186 · 16.53%
EPS
$-0.10 · 24.77%
Op Income
$-4,164,020
FCF YoY
8.16%

Performance & Tape

52W High
$0.01
52W Low
$0.00
50D MA
$0.00
200D MA
$0.00
Beta
1.42
Avg Volume
1.03K

Get TickerSpark's AI analysis on CTABF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Our CTABF Coverage

We haven't published any research on CTABF yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate CTABF Report →

Similar Companies